Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Pharmacokinetics of doxorubicin (DOX), epidoxorubicin (EPI), and their metabolites in plasma have been performed in eight patients receiving 40 to 56 mg/m2 of both anthracyclines as a bolus injection in two sequential cycles. Terminal half-life and volume of distribution appeared to be smaller in case of EPI, whereas plasma clearance and cumulative urinary excretion was larger in comparison to DOX. The major metabolite of DOX was doxorubicinol (Aol) followed by 7-deoxy-doxorubicinol (7d-Aolon). Metabolism to glucuronides was found in case of EPI only. The area under the curves (AUC) of the metabolites of EPI decreased in the order of the glucoronides E-glu greater than Eol-glu, 7d-Aolon greater than epirubicinol (Eol). The AUC of Eol was half of the value in its counterpart Aol. In the case of EPI, the AUC of 7d-Aolon was twice the level of that of the corresponding metabolite of DOX. The terminal half-lives of the cytostatic metabolites Aol and Eol were similar, but longer than the corresponding values of their parent drugs. Half-lives of the glucuronides (E-glu, Eol-glu) were similar to the half-life of their parent drug. 7d-Aolon had a somewhat shorter half-life in comparison to both DOX and EPI. Approximately 6.2% of EPI and 5.9% of DOX were excreted by the kidney during the initial 48 hours. Aol was found in the urine of patients treated with DOX, whereas Eol, E-glu, and Eol-glu were detected in urine of patients treated with EPI. The cumulative urinary excretion appeared to be 10.5% for EPI and its metabolites, and 6.9% for DOX and its metabolite. The plasma concentration v time curves of (7d)-aglycones showed a second peak between two and 12 hours after injection, suggesting an enterohepatic circulation for metabolites lacking the daunosamine sugar moiety. The plasma concentrations of the glucuronides were maximal at 1.2 hours for E-glu and 1.9 hours for Eol-glu. All other compounds reached their maximum plasma concentration during the first minutes after the administration of DOX and EPI. Deviating plasma kinetics were observed in one patient, probably due to prior drug administration.
Mross
K
K
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Maessen
P
P
van der Vijgh
W J
WJ
Gall
H
H
Boven
E
E
Pinedo
H M
HM
D000328:Adult; D003520:Cyclophosphamide / Q000378:metabolism; D004317:Doxorubicin / Q000378:metabolism / Q000493:pharmacokinetics* / Q000633:toxicity; D015251:Epirubicin; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D006207:Half-Life; D006321:Heart / Q000187:drug effects; D006801:Humans; D008107:Liver Diseases / Q000378:metabolism; D008875:Middle Aged
D005965:Glucuronates; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide